Winslow Evans & Crocker Inc. lowered its position in Laboratory Corp. of America Holdings (NYSE:LH) by 0.8% during the second quarter, Holdings Channel reports. The fund owned 9,208 shares of the company’s stock after selling 70 shares during the period. Winslow Evans & Crocker Inc.’s holdings in Laboratory Corp. of America Holdings were worth $1,200,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LH. Integrated Investment Consultants LLC raised its position in Laboratory Corp. of America Holdings by 56.3% in the second quarter. Integrated Investment Consultants LLC now owns 938 shares of the company’s stock worth $122,000 after buying an additional 338 shares during the last quarter. Hall Laurie J Trustee purchased a new position in Laboratory Corp. of America Holdings during the second quarter worth about $152,000. Brick & Kyle Associates raised its position in Laboratory Corp. of America Holdings by 3.0% in the first quarter. Brick & Kyle Associates now owns 1,368 shares of the company’s stock worth $160,000 after buying an additional 40 shares during the last quarter. Regentatlantic Capital LLC purchased a new position in Laboratory Corp. of America Holdings during the second quarter worth about $207,000. Finally, Canada Pension Plan Investment Board raised its position in Laboratory Corp. of America Holdings by 16.2% in the first quarter. Canada Pension Plan Investment Board now owns 2,112 shares of the company’s stock worth $247,000 after buying an additional 295 shares during the last quarter. 92.11% of the stock is currently owned by hedge funds and other institutional investors.

Laboratory Corp. of America Holdings (NYSE:LH) traded up 0.52% during midday trading on Friday, reaching $135.38. The company had a trading volume of 802,175 shares. Laboratory Corp. of America Holdings has a 52-week low of $97.79 and a 52-week high of $141.32. The company has a market cap of $13.85 billion, a PE ratio of 22.48 and a beta of 0.85. The company’s 50-day moving average is $138.33 and its 200 day moving average is $127.76.

Laboratory Corp. of America Holdings (NYSE:LH) last released its earnings results on Wednesday, July 27th. The company reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Laboratory Corp. of America Holdings had a return on equity of 17.01% and a net margin of 6.64%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.33 billion. During the same quarter in the prior year, the firm posted $2.09 earnings per share. The company’s quarterly revenue was up 7.4% on a year-over-year basis. On average, equities research analysts forecast that Laboratory Corp. of America Holdings will post $8.81 EPS for the current year.

A number of research analysts recently issued reports on LH shares. KeyCorp reaffirmed a “buy” rating and set a $143.00 target price on shares of Laboratory Corp. of America Holdings in a report on Sunday, May 22nd. SunTrust Banks Inc. reissued a “buy” rating on shares of Laboratory Corp. of America Holdings in a research note on Thursday, July 28th. Canaccord Genuity set a $155.00 price target on Laboratory Corp. of America Holdings and gave the stock a “buy” rating in a research note on Thursday, July 28th. Evercore ISI lifted their price target on Laboratory Corp. of America Holdings from $147.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, July 27th. Finally, Barclays PLC set a $155.00 price target on Laboratory Corp. of America Holdings and gave the stock a “buy” rating in a research note on Monday, August 29th. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Laboratory Corp. of America Holdings presently has an average rating of “Buy” and an average target price of $140.86.

In other Laboratory Corp. of America Holdings news, Director Robert E. Mittelstaedt, Jr. sold 992 shares of the stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $140.15, for a total value of $139,028.80. Following the completion of the sale, the director now directly owns 12,340 shares in the company, valued at $1,729,451. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Glenn A. Eisenberg sold 8,000 shares of the stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $140.10, for a total value of $1,120,800.00. Following the completion of the sale, the chief financial officer now owns 8,668 shares of the company’s stock, valued at $1,214,386.80. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

About Laboratory Corp. of America Holdings

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

5 Day Chart for NYSE:LH

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Receive News & Ratings for Laboratory Corp. of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.